A comparative study of patoladi kwath and hapushadi yapan vasti in vatarakta
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- reduction in subjective parameters according to the specific grading given to each symptoms like burning, pain, skin discoloration, redness, stiffness, tenderness, numbness, heaviness, swelling, deformity in joint involved and pain on joint movement.
研究概览
简要总结
A total of 40 patients of vatarakta will be selected from opd and ipd of pg department of kayachikitsa uau, gurukul campus, haridwar. The study will be conducted on the patients randomly divided into 2 groups that is 20 patients in each group on the basis of inclusion and exclusion criteria depending on detailed clinical history, physical examination and other necessary and desired investigation. The patients will be followed up at every 15 days after completion of trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Random Number Table
- 盲法
- Open Label
入排标准
- 年龄范围
- 18.00 Year(s) 至 65.00 Year(s)（—）
- 性别
- All
入选标准
- •Well diagnosed patients of Vatarakta.
- •(Diagnosis will be made on the basis of assessment criteria as mentioned in classical texts & modern medical science.) Both previously treated and fresh cases will be taken.
- •Patients of either sex.
- •Increased serum uric acid levels of more than 7mg/dl in males and 6mg/dl in females.
排除标准
- •Patients of Vatarakta with any chronic systemic disorder which interferes with the present study.
- •Patients of age below 18 or more than 70 years.
- •Patients of Vatarakta having any severe arthritic condition (like R.A.) will be excluded .
- •Patients of Vatarakta with conditions like haemarthrosis, Koch’s arthritis, septic arthritis, chronic kidney disease.
- •Patients with serious medical illness and psychiatric disorder will be excluded.
- •Cases with alcohol dependence/ misuse and drug abuse.
结局指标
主要结局
reduction in subjective parameters according to the specific grading given to each symptoms like burning, pain, skin discoloration, redness, stiffness, tenderness, numbness, heaviness, swelling, deformity in joint involved and pain on joint movement.
时间窗: the patient will be followed up at every 15 days for one month after completion of treatment.
mild-1
时间窗: the patient will be followed up at every 15 days for one month after completion of treatment.
moderate-2
时间窗: the patient will be followed up at every 15 days for one month after completion of treatment.
no sign-0
时间窗: the patient will be followed up at every 15 days for one month after completion of treatment.
severe-3
时间窗: the patient will be followed up at every 15 days for one month after completion of treatment.
Also reduction in objective parameters of serum uric acid.
时间窗: the patient will be followed up at every 15 days for one month after completion of treatment.
次要结局
- reduction in erythrocyte sedimentation rate.(exacerbation of symptoms.)